Advancements in cancer treatments have always been a focal point in medical research. Mustang Bio, Inc. (Nasdaq: MBIO) has recently made significant strides in the battle against Waldenstrom macroglobulinemia (WM), a rare type of blood cancer. Their latest clinical trial results for MB-106, a
The biopharma industry stands at the crossroads of innovation and necessity as it leans into the burgeoning field of immunology. With the global immunology market anticipated to grow exponentially in the coming years, reaching numbers second only to oncology, major players and emerging startups
Throughout 2023 and 2024, the U.S. Food and Drug Administration (FDA) played a pivotal role in the pharmaceutical and biotechnology sectors, not only by approving a significant number of new drugs but also by pushing the boundaries of innovation. These two years were marked by a notable surge in
The landscape of medical treatment and drug development is experiencing a new dawn as the U.S. Food and Drug Administration (FDA) plays a pivotal role in ushering in an era where the once unimaginable becomes reality. With a discerning eye on cutting-edge therapies, especially in gene therapy and
In the rapidly advancing field of nuclear radiation therapy, a groundbreaking treatment is emerging, promising to redefine the landscape of medical response to nuclear events. Financed by the backing of a weighty $4.2 million agreement with the National Institute of Allergy and Infectious Diseases
As the field of medical research forges ahead, certain pioneering companies are facing a formidable hurdle. MMJ BioPharma Labs and MMJ International Holdings, at the forefront of developing cannabis-based pharmaceuticals, find themselves entangled in a problematic scenario with the Drug Enforcement
